CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabineRaphaëlle Fanciullino, Régis Costello, Laure Farnault et al.|Blood Advances|2018Cited by 43
Use of platelet-rich plasma in regenerative medicine: technical tools for correct quality controlHajer Graiet, Jérémy Magalon, Anna Lokchine et al.|BMJ Open Sport & Exercise Medicine|2018Cited by 20
Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patientsMélanie Donnette, Raphaëlle Fanciullino, Caroline Solas et al.|Journal of Chromatography B|2019Cited by 12
Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351Mélanie Donnette, Raphaëlle Fanciullino, Joseph Ciccolini et al.|Journal of Controlled Release|2021Cited by 9
Could daratumumab induce the maturation of plasmablasts in Plasmablastic lymphoma?—Potential therapeutic applicationsPauline Roché, Laure Farnault, Geoffroy Venton et al.|European Journal Of Haematology|2021Cited by 4